about
Kes1p shares homology with human oxysterol binding protein and participates in a novel regulatory pathway for yeast Golgi-derived transport vesicle biogenesis.Clinical effects of reverting from leukoreduced to nonleukoreduced blood in cardiac surgery.Validation of HLAMatchmaker algorithm in identifying acceptable HLA mismatches for thrombocytopenic patients refractory to platelet transfusions.Utility of cross-matched platelet transfusions in patients with hypoproliferative thrombocytopenia: a systematic review.Platelet transfusion: a clinical practice guideline from the AABB.Guidance on platelet transfusion for patients with hypoproliferative thrombocytopenia.Monthly haemostatic factor variability in women and men.Red blood cell transfusion: a clinical practice guideline from the AABB*.Curriculum content and evaluation of resident competency in clinical pathology (laboratory medicine): a proposal.Recent Advances in Preventing Adverse Reactions to TransfusionEducating medical students in laboratory medicine: a proposed curriculum.Using HLA typing to support patients with cancer.Warm-reactive (immunoglobulin G) autoantibodies and laboratory testing best practices: review of the literature and survey of current practice.An international survey on the role of the hospital transfusion committee.International validation of a dithiothreitol (DTT)-based method to resolve the daratumumab interference with blood compatibility testing.AABB validation study of the CDC's National Healthcare Safety Network Hemovigilance Module adverse events definitions protocol.Blood Group Antigen Matching Influence on Gestational Outcomes (AMIGO) study.Attitudes, Practices, and Training on Informed Consent for Transfusions and Procedures: A Survey of Medical Students and Physicians.Vitamin K and oral anticoagulation: thought for food.Factors affecting red blood cell storage age at the time of transfusion.Severe hemolysis resulting from D incompatibility in a case of ABO-identical liver transplant.Evaluation of the Wampole Laboratories ELISA-based assay for Epstein-Barr virus serology.Should DEHP be eliminated in blood bags?Classification of posttransfusion adverse events using a Web-based algorithm.Challenges and opportunities to prevent transfusion errors: a Qualitative Evaluation for Safer Transfusion (QUEST).Transfusion of platelets containing ABO-incompatible plasma: a survey of 3156 North American laboratories.Permanently removing AB red blood cells from inventory: a case for conserving scarce AB plasma.Is blood donation an opportunity for hypertension awareness?Blood component preferences of transfusion services supporting infant transfusions: a University HealthSystem Consortium benchmarking study.Induction of platelet white blood cell (WBC) aggregate formation by platelets and WBCs in red blood cell units.Obstetrics and gynecology physician knowledge of Rh immune globulin prophylaxis.Counting platelets at transfusion threshold levels: impact on the decision to transfuse. A BEST Collaborative - UK NEQAS(H) International Exercise.Prevention of treatment-related fluid overload reduces estimated effective cost of prothrombin complex concentrate in patients requiring rapid vitamin K antagonist reversal.Leukoreduction in the setting of open heart surgery: a prospective cohort-controlled study.The Clinical Pathologist as ConsultantCurriculum content and evaluation of resident competency in clinical pathology (laboratory medicine): a proposalA proposal for curriculum content in transfusion medicine and blood banking education in pathology residency programsAntibodies to low-incidence antigens: do we need a different set of rules in prenatal laboratory evaluation?Curriculum content and evaluation of resident competency in clinical pathology (laboratory medicine): a proposalPlatelet-rich plasma injections: out of control and on the loose?
P50
Q27939089-B6819E9B-812A-4AE1-A35C-341CC5906B87Q33236246-05FA8E8A-F828-45CD-8000-401AA8ABF82DQ33380390-67677E0D-C638-41C1-9520-12DE3E492F9DQ33410314-517A3CD4-B8A6-4324-839F-52850479C652Q33418628-38E92F7B-B49E-48A2-AD47-DF9416B24FBCQ33419477-E4E7FC2A-42DA-4ECB-8190-4DABAA9A883BQ34129736-8688E430-01DB-400D-AAA8-7EE5AA598D15Q34285364-ACD7271B-34C2-491C-ACC4-5EF4321EA5A3Q36531942-08662CEA-BDB2-45BE-9C39-B2DD4068104FQ36750167-CFEC61AB-4D9E-4B19-9939-217A7702048CQ37709781-5E7E6AD9-9FCC-4ECF-AB9F-2A954CB344E4Q38287616-A0820D9C-30C0-4F46-826C-5861298E4C82Q38787272-232112DD-70E5-4DD8-8C18-6A0686580923Q39150162-54D8325D-6BC7-48F0-884F-EE449D80ADAFQ39417506-7B222DAD-6306-4383-9740-C298F10F270BQ40212823-510BC776-DF1A-4AB9-925D-D7258BFFF55AQ40348688-C3693D14-AEE4-4F96-B98A-888AED05D3C9Q40725636-E16F9E56-BCD3-4A30-9757-0996BF0986F3Q44879423-6894EE04-99ED-47D1-9370-42C3EF46496EQ45051724-0A8339F4-5CE3-475F-9862-9B61250F887BQ45123615-20F28CB4-EA89-4E9F-8607-5FF62EBF2BEBQ45733112-97C72AA5-0382-40E0-893C-75BCED3F6559Q46444087-07F1C7F3-672F-4814-8C82-0C2E0BFCFCBDQ47973260-A2EEF824-40BB-454B-9E66-DAF807CE06EBQ50147413-B29BEF2B-E8BA-4BE4-A3A9-D68243BD4A8FQ50156678-7DD347CF-96FF-4CAD-933B-B36C8B860F4FQ50215876-C933D780-C299-42DC-BBF0-3341F1299A4DQ50247806-75A00B0E-D512-45B9-8A46-601EF9FF0D32Q50578069-78CD4DE6-799C-41BB-9C13-404E89514116Q50654530-874A8E97-A181-4DEB-BE8C-11C89491BA53Q51051478-3BCA74B0-73D2-4F15-912A-8B294E428617Q53098496-00BE5260-0F6A-4895-8D3A-A21E5FE057F1Q53605770-91D03F8D-52C2-4F2A-AA23-04C801E5F868Q53850593-D2399C80-B5F5-4BC2-B49E-4EF202A68E81Q56794840-8A354DD1-4C74-454B-B43E-8ECCC080ADAAQ79987588-599810AC-9129-4334-8608-F59396D29D81Q81322597-2D5AE27F-F600-442A-8D25-8500D260C2AAQ81492097-6412D567-99CE-43F8-98D4-C46DE85FBDD3Q82995291-B3FE8892-39FC-4EFB-86A8-E98A35B80445Q85587562-8EF4B944-0A8D-4916-94FE-21EB023C0B13
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Mark Fung
@ast
Mark Fung
@en
Mark Fung
@es
Mark Fung
@nl
Mark Fung
@sl
type
label
Mark Fung
@ast
Mark Fung
@en
Mark Fung
@es
Mark Fung
@nl
Mark Fung
@sl
prefLabel
Mark Fung
@ast
Mark Fung
@en
Mark Fung
@es
Mark Fung
@nl
Mark Fung
@sl
P106
P21
P31
P496
0000-0001-6081-4151